Allarity Therapeutics (NASDAQ:ALLR) Releases Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Allarity Therapeutics (NASDAQ:ALLR) issued its quarterly earnings results on Monday. The company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.01, FiscalAI reports.

Allarity Therapeutics Trading Down 2.8%

Shares of ALLR traded down $0.03 during mid-day trading on Monday, hitting $1.04. The company’s stock had a trading volume of 58,908 shares, compared to its average volume of 169,916. Allarity Therapeutics has a 1-year low of $0.61 and a 1-year high of $2.35. The firm has a market capitalization of $16.72 million, a P/E ratio of -1.76 and a beta of 0.20. The firm has a 50-day simple moving average of $1.05 and a 200 day simple moving average of $1.22.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the business. Private Advisor Group LLC acquired a new stake in Allarity Therapeutics in the third quarter valued at $441,000. Renaissance Technologies LLC grew its stake in shares of Allarity Therapeutics by 274.1% during the 4th quarter. Renaissance Technologies LLC now owns 247,612 shares of the company’s stock worth $267,000 after purchasing an additional 181,426 shares during the period. DRW Securities LLC acquired a new position in shares of Allarity Therapeutics during the 4th quarter worth $133,000. Citadel Advisors LLC purchased a new position in shares of Allarity Therapeutics in the 3rd quarter valued at about $149,000. Finally, XTX Topco Ltd purchased a new position in shares of Allarity Therapeutics in the 2nd quarter valued at about $51,000. Hedge funds and other institutional investors own 11.53% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Allarity Therapeutics in a research note on Wednesday, January 21st. Ascendiant Capital Markets lifted their target price on shares of Allarity Therapeutics from $9.25 to $9.50 and gave the company a “buy” rating in a report on Tuesday, December 9th. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $9.50.

Allarity Therapeutics Company Profile

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.